NCT07054346 - Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions

Prostate CancerProstate Cancer (Diagnosis)High-risk Prostate CancerLocalized Prostate CarcinomaVery High Risk Prostate Carcinoma

Interventions

DRUG

177 Lutetium Prostate-Specific Membrane Antigen 617

Given intravenously (IV) or intra-arterially (IA)

DRUG

Actinium-225 Prostate-Specific Membrane Antigen 617

Given IV or IA

PROCEDURE

Non-investigational, Prostatectomy

Undergo non-investigational surgical procedure to remove prostate.

PROCEDURE

Prostate Tissue Collection

Whole prostate tissue will be collected for correlative research at time of prostatectomy.

PROCEDURE

Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)

Imaging procedure

PROCEDURE

Blood Sample Collection

Blood samples will be obtained for research purposes

Trial Locations (1)

University of California, San Francisco, San Francisco